Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Biochemical Pharmacology|December 21, 2024
The PROTAC selectively degrading BCL-X<sub>L</sub> inhibits the growth of tumors and significantly synergizes with PaclitaxelFenglan Qiu, Yachuan Tao, Yue Chen, et al.
Journal of Pharmacological Sciences|August 2, 2013
Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell propertiesHong Xin, Ying Kong, Xiaoxiao Jiang, et al.
International Journal of Medical Sciences|July 24, 2023
SNHG3/hsa-miR-455-5p Axis-mediated High Expression of MTHFD2 Correlates with Tumor Immune Infiltration and Endometrial Carcinoma ProgressionSa Wu, Weisong Cai, Yanli Li, et al.
European Journal of Medicinal Chemistry|July 9, 2017
Design, synthesis, and biological evaluation of optimized phthalazine derivatives as hedgehog signaling pathway inhibitorsXiuhong Lu, Yuanqiu Peng, Chenglin Wang, et al.
Journal of Medicinal Chemistry|September 6, 2017
Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated TranscriptionGang Liu, Wenjing Huang, Juan Wang, et al.
Biochemical Pharmacology|October 25, 2023
BRD4-binding enhancer promotes CRC progression by interacting with YY1 to activate the Wnt pathway through upregulation of TCF7L2Biao Duan, Xuwei Zhou, Xiaoyi Zhang, et al.
Acta Pharmaceutica Sinica. B|March 1, 2021
Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastomaXiaohua Liu, Yu Zhang, Yalei Li, et al.
Theranostics|November 28, 2022
The PROTAC selectively degrading Bcl-x<sub>L</sub> represents a novel Hedgehog pathway inhibitor with capacity of combating resistance to Smoothened inhibitors while sparing bone growthShaoqing Zhang, Yue Chen, Zhongli Xu, et al.
Journal of Medicinal Chemistry|October 14, 2016
Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-aryl Propanamides as Novel Smoothened (Smo) AntagonistsGang Liu, Ding Xue, Jun Yang, et al.
Science Signaling|September 22, 2011
A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cellsHiroshi Yagi, Wenfu Tan, Patricia Dillenburg-Pilla, et al.
Pageof 5